Abstract
Sustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma (MM). The gut microbiome is affected by diet, and in turn can modulate host immunity, for example through production of short-chain fatty acids including butyrate. We examined the relationship of dietary factors, stool metabolites, and microbial diversity with sustained MRD negativity in patients on lenalidomide maintenance. At 3 months, higher stool butyrate concentration (p=0.037), butyrate producers (p=0.025) and α-diversity (p=0.0035) were associated with sustained MRD-negativity. Healthier dietary proteins, (from seafood and plants), correlated with butyrate at 3 months (p=0.009) and sustained MRD-negativity (p=0.05). Consumption of dietary flavonoids, plant nutrients with antioxidant effects, correlated with stool butyrate concentration (anthocyanidins p=0.01, flavones p=0.01, and flavanols p=0.02). This is the first study to demonstrate an association between a plant-based dietary pattern, stool butyrate production and sustained MRD-negativity in MM; providing rationale to evaluate a prospective dietary intervention.
Statement of Significance We demonstrate an association between diet, the gut microbiome, and sustained MRD-negativity in MM. A healthy diet, with adequate plant and seafood protein, and containing flavonoids, associates with stool diversity, butyrate production and sustained MRD-negativity. These findings suggest dietary modification should be studied to enhance myeloma control.
Key Points
In MM on lenalidomide maintenance, stool butyrate concentration at 3 months was associated with higher rates of MRD negativity at 12 months.
Increased seafood and plant proteins, dietary flavonoids, and diversity of dietary flavonoids correlated with stool butyrate concentrations.
Competing Interest Statement
UAS has received grants and research support from Celgene/Bristol Myers Squibb, Janssen paid to the institution, personal fees from Janssen, MJH LifeSciences, ACCC all outside of the submitted work. SG reports personal fees and advisory role (scientific advisory board) from Actinnum, Celgene, Bristol Myers Squibb, Sanofi, Amgen, Pfizer, GlaxoSmithKline, JAZZ, Janssen, Omeros, Takeda, and Kite, outside the submitted work. HH reports grants from Celgene, during the conduct of the study; and grants from Celgene, Takeda, and Janssen, outside the submitted work. NK reports research funding through Amgen and participates in advisory board with Medimmune. NK reports research funding through Amgen and participates in advisory board with Medimmune. OLah reports serving on Advisory Board for MorphoSys. OLan reports grants from Amgen, Janssen, and Takeda; Data Monitoring Committee from Janssen, Merck, and Takeda; and personal fees from Amgen, Janssen, GlaxoSmithKline, AstraZeneca, and The Binding Site, outside the submitted work. SM reports research funding from Allogene Therapeutics, Juno/Bristol Myers Squibb, Takeda Oncology, and Janssen Oncology; personal fees from Plexus communication, and Physician Education Resource, outside the submitted work. AML reports grants from Novartis, during the conduct of the study; grants from Bristol Myers Squibb; personal fees from Trillium Therapeutics; grants, personal fees and support from Pfizer, and grants and personal fees from Janssen, outside the submitted work. AML also has a patent US20150037346A1 with royalties paid. MS reports personal fees and research funding from Angiocrine Bioscience and Omeros Corporation; personal fees from McKinsey & Company, Kite, A Gilead Company, and i3Health, outside the submitted work. GLS reports research funding from Janssen and Amgen outside the submitted work. MJP reports research funding from Trillium Therapeutics, Nektar Therapeutics, and Regeneron Pharmaceuticals; personal fees from Karyopharm, Oncopeptides, Takeda, Janssen, and Curio Science, MJH Life Sciences, outside the submitted work. CT reports other from Janssen Research and Development outside the submitted work. BD reports honoraria from Medscape and Sanofi outside the submitted work. SZU reports grant support from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX and Takeda; personal fees from Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda and TeneoBio; outside the submitted work. JUP reports research funding, intellectual property fees, and travel reimbursement from Seres Therapeutics, and consulting fees from DaVolterra, CSL Behring, and from MaaT Pharma. He serves on an Advisory board of and holds equity in Postbiotics Plus Research. He has filed intellectual property applications related to the microbiome (reference numbers #62/843,849, #62/977,908, and #15/756,845). MVDB has received research support and stock options from Seres Therapeutics and stock options from Notch Therapeutics and Pluto Therapeutics; he has received royalties from Wolters Kluwer; has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, WindMIL Therapeutics, Rheos Medicines, Merck & Co, Inc., Magenta Therapeutics, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Forty Seven Inc., Ceramedix, Lygenesis, Pluto Therapeutics, GlaskoSmithKline, Da Volterra, Novartis (Spouse), Synthekine (Spouse), and Beigene (Spouse); he has IP Licensing with Seres Therapeutics and Juno Therapeutics; and holds a fiduciary role on the Foundation Board of DKMS (a nonprofit organization). The remaining authors declare no potential conflicts of interest.
Clinical Trial
NCT02538198
Funding Statement
This study is funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748, Sawiris Family Fund, Paula and Rodger Riney Foundation and Celgene. U.A.S. received research support from the American Society of Hematology Clinical Research Training Institute, Parker Institute for Cancer Immunotherapy, International Myeloma Society, Paula and Rodger Riney Foundation, TREC Training Workshop R25CA203650 (PI: Melinda Irwin), NCI MSK Paul Calabresi Career Development Award for Clinical Oncology K12 CA184746, HealthTree Foundation and the Allen Foundation Inc. K.H.M received research support from a Multiple Myeloma Research Foundation Fellow Award, an American Society of Hematology Restart Research Award and a Royal Australasian College of Physicians Research Establishment Grant. MJP received research support from National Institutes of Health grants (National Institute of Aging: P30-AG024824; National Cancer Institute: P30-CA046592, and the National Center for Advancing Translational Sciences award UL1-TR00457. AML received research support from NCI 1R01CA249981-01, Sawiris Family Fund and Paula and Rodger Riney Foundation. JUP reports funding from NHLBI NIH Award K08HL143189, the MSKCC Cancer Center Core Grant NCI P30 CA008748. This research was supported by the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center; J.U.P is a member of the Parker Institute for Cancer Immunotherapy. MVDB was supported by National Cancer Institute award numbers, R01-CA228358, R01-CA228308, and P01-CA023766; National Heart, Lung, and Blood Institute (NHLBI) award number R01-HL123340 and R01-HL147584; National Institute of Aging award number P01-AG052359; Starr Cancer Consortium, and Tri Institutional Stem Cell Initiative. Additional funding was received from The Lymphoma Foundation, The Susan and Peter Solomon Divisional Genomics Program, Cycle for Survival, and the Parker Institute for Cancer Immunotherapy. AML received research support from NCI 1R01CA249981-01, Sawiris Family Fund and Paula and Rodger Riney Foundation. Authorship Contributions UAS and AML conceived and designed the study. UAS, KHM, AD, AML analyzed, verified, and interpreted the data MS, KW, JC, JB, LT, AC, MB, TS, PA, MJP, SM, NK, MH, HH, CT, BD, SL, DP, GS, MS, OLah, DC, HL, SU, OLan, SG collected and assembled the data. JC, YT, JUP, MVDB, UAS, AML, AD, KHM analyzed and interpreted the microbiome data. GB, TB, UAS, AML, AD, KHM analyzed and interpreted the nutrition data. UAS, KHM, AML had full access to the data and share final responsibility for submission of the publication. All authors wrote and approved of the article and are accountable for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Memorial Sloan Kettering Cancer Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Statement of prior presentation Presented in abstract form at the meeting of the International Myeloma Society, Vienna, Austria, September 10, 2021.1
1 Shah U, Derkach A, Adintori P, et al. P-042: Sustained minimal residual disease negativity in Multiple Myeloma is impacted positively by stool butyrate and healthier plant forward diets. Clinical Lymphoma, Myeloma and Leukemia. 2021;21:S61.
Data Availability
All data produced in the present work are contained in the manuscript.
